Background: One million people worldwide benefit from chronic dialysis, with an increased rate in Western countries of 5% yearly. Owing to increased incidence of cancer in dialyzed patients, the management of these patients is challenging for oncologists/nephrologists.
introduction
Since the demonstration in the 1940s that hemodialysis (HD) can sustain life and relieve the symptoms of uremia, the widespread access to dialysis that began in the 1970s has been life-saving for patients with acute kidney failure or end-stage renal disease (ESRD). Today, over 1 million people worldwide benefit from long-term dialysis. The number of patients under dialysis increases by at least 5% per year in Western countries due to aging and increasing prevalence of type II diabetes, a condition that is frequently associated with the deterioration of renal function. Substantial improvements of chronic renal replacement therapy have led to prolonged survival. Despite conflicting results among various studies in the 1990s, there is now sufficient evidence to conclude that there is a higher incidence of at least some cancers in dialysis patients [1] [2] [3] [4] [5] [6] . In a large cohort of Australian ESRD patients, the authors reported a higher incidence of all types of cancer in dialysis patients compared with non-dialysis pre-ESRD patients with a standardized incidence ratio of 1.35 (95% confidence interval 1.27-1.45) [2] . Further, in a recent study, the authors prospectively followed 454 HD patients and reported a 65% 3-year survival rate. Twelve percent of deaths were due to cancer, thus ranking third after cardiovascular (52%) and infectious diseases (25%) [7] . Furthermore, the survival rate of ESRD patients with cancer is lower compared with that of ESRD cancer patients without cancer [8] . Finally, mortality rate is also high in cancer patients with acute renal dysfunction [9] .
Plausible mechanisms of carcinogenesis under chronic dialysis include chronic oxidative stress, compromised immune system, viral infections and some drugs, and some renal disease such as acquired cystic kidney disease [10] .
Dialysis patients are immunocompromised. The mechanisms include impaired cell-mediated and humoral immunity and reduced activities of the immune system cells (B cell, T cell, monocytes, macrophages) [11, 12] . Furthermore, this immune dysfunction exposes these patients more to viral infections that could be responsible for cancer, such as hepatitis B and C, Epstein-Barr virus, and so on [2] .
Some drugs used for glomerulonephritides or vasculitides can predispose to the development of cancer. For example, azathioprine is associated with an increased risk of skin cancer and lymphoma [10] ; and cyclophosphamide increases the risk of bladder carcinoma [10, 13] . Noteworthy, patients with ESRD display enhanced genomic damages that may have pathophysiologic relevance for cancer development [14] . These damages were possibly due to the accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic properties, which are increased in dialysis patients, could be involved, such as the blood pressure-regulating hormones angiotensin II and aldosterone or the inflammatory cytokine TNF [15] .
Because of this increasingly prevalent population, oncologists will be more likely to face the question of anticancer drug handling in dialysis patients. Prescriptions will have to be adapted in terms of dosage adjustment and time of administration regarding dialysis sessions, in order to (i) prevent non-renal side-effects due to pharmacokinetics modifications of anticancer drugs in those patients and thus undue toxic effects and (ii) prevent early drug elimination during the dialysis procedure and subsequent lower dose intensity and efficacy. The main objective of the CANDY study was to assess the management of cancer drugs in dialysis patients who developed cancer after the initiation of dialysis.
methods design and setting
The retrospective multicentric CANDY study included 178 dialysis patients who developed cancer from 1997 to 2010, after the initiation of chronic dialysis in 12 centers. Patients with previous cancer (before dialysis) were not included in the study. The study consisted of a retrospective patient data collection (www.easy-crf.com database). Patients were included regardless of renal and cancer diseases.
selection of participants, data collection, and definitions
Patients were not included if they were <18 years of age, had had a previous renal transplantation, or were dialyzed for acute renal failure. Institutional Review Board approval was obtained. Each patient was followed up for 2 years after cancer diagnosis (T0). Data were collected at T0, 1 month, 6 months, 1 year, and 2 years after the diagnosis of cancer. Anticancer drugs requiring dosage adjustment were identified in accordance with their pharmacokinetics and available recommendations from their individual summary of product characteristics, from two specific reference books on drug dosage adjustment in patients with renal insufficiency (RI) (Drug prescribing in renal failure dosing guidelines for adults [16] , GPR Anticancéreux focused on anticancer drugs [17] ) and from one website (www.sitegpr.com). Anticancer drugs were then classified as 'Yes' when adjustment was required, 'No' when adjustment was not necessary, and 'ND' (not determined) when no data were available in the literature. The same methodology was used to identify the drugs which needed to be used after the dialysis session. Some data of the CANDY study were compared with the French ESRD population (2009 annual report of the REIN registry).
data presentation and statistical analysis
All the data management and analyses were carried out with the SAS statistical software, version 8.02 (SAS, Inc., Cary, NC). Survival was calculated from the date of cancer diagnosis until the date of death. Data concerning patients without any event at the last follow-up were censored. Survival curves were derived from Kaplan-Meier estimates results
patients
Of the 178 patients included in the analysis, 66% were men. The mean/median ages of all patients at the dialysis onset and at cancer diagnosis were 65/67 and 67/69 years, respectively. The mean period between the beginning of the dialysis and cancer diagnosis was 2.6 years. Table 1 shows the population characteristics. The most common causes of ESRD were hypertensive nephropathy (28%), diabetic nephropathy (18%), and chronic glomerulonephritis (13%).
The main primary cancer sites were genito-urinary (21%) ( Table 1) , hematologic (15%), lung (13%), gastrointestinal (13%), prostate (8%), and head and neck cancers (7%). The remaining ones were miscellaneous cancers. There was no relationship between age and tumor type, except for head and neck cancers, for which patients were younger (P = 0.03). Only a few patients had skin cancer in the CANDY study.
At cancer diagnosis, 74% of the patients presented with anemia according to the European Renal Best Practice (ERBP) and the Kidney Disease Outcomes Quality Initiative (K/DOQI) [18, 19] . At the same period, 37% of the dialysis patients were receiving erythropoietin-stimulating agents, likely indicating anemia induced by chronic renal failure and 12% received iron supplementation.
Regarding non-systemic treatments, 37% and 21% of the patients underwent surgery and radiotherapy, respectively, and 5% had both treatments at the observational time points of data collections.
anticancer drugs
Among the 178 CANDY patients, 28% received anticancer drugs at the time points of data collections. The prescription included 36 different drugs (Table 2) . Of the 96 prescriptions overall, 45% either required drug dosage adjustment or there were no available recommendations in dialysis patients (Figures 1 and 2 ). Of these drug prescriptions, 75% required administration after dialysis sessions according to available recommendations [17] . Of the 50 patients undergoing anticancer drug treatment, 72% received at least one drug that required a dosage adjustment or for which there were no data in dialysis patients (Figures 1 and 2 ). In these patients, 82% had drugs requiring administration after dialysis sessions. Overall, 88% of the patients who received anticancer drugs needed a specific drug management regarding dose adjustment and/or time of administration according to the dialysis session of at least one anticancer drug. A total of 44% of the treated patients developed iatrogenic toxicity: 34% related to drugs requiring dosage adjustment, and 17% additional drugs with no existing management recommendations in dialysis patients. Unfortunately, detailed toxicity descriptions were not recorded comprehensively, thus hampering precise assessment of toxic effects.
The most common drugs used were DNA cross-linking drugs (33% of the prescriptions), anti-metabolite drugs (18%), hormonal therapies (8%), tubulin inhibitors (8%), intercalating agents (8%), proteasome inhibitors (7%), monoclonal antibodies (7%), tyrosine kinase inhibitors (4%), bisphosphonates (2%), immune system drugs (1%), immunomodulators (1%), and trabectidin (1%) ( Table 2) .
the time of cancer development in ESRD patients
In all patients, the mean and median times for cancer development after the beginning of the dialysis sessions were 30.8 and 13 months, respectively. Indeed, after ∼1 year, half of the patients had developed cancer. As the mean and median times were quite different among cancer types, the same data were analyzed separately. Early diagnoses were observed in prostate cancer, while the latest occurrence noted was head and neck cancer (Table 3) . Hematologic malignancies were diagnosed ∼2 years after dialysis onset. mortality Fifty-eight percent of the CANDY patients died during the 2-year follow-up period after cancer diagnosis. The median survival time was 13.5 months after the diagnosis of malignancy (Table 3) . Interestingly, 38% of the CANDY patients died within a period of 2 years after dialysis onset versus 28% in the French REIN registry. Most deaths (48%) were related to cancer in the CANDY study. [15] . Noteworthy, many patients had cancer diagnosed during their first year of dialysis, possibly suggesting an effect of cancer screening for a renal transplant program. Cancer is an important cause of mortality among patients with chronic kidney disease [20] . Indeed, renal impairment has been found to be linked to mortality in cancer patients in at least two studies [21, 22] . The first study included 1155 lung cancer patients with various comorbidities, among them 5.9% presented RI, and the 5-year follow-up mortality analysis found a relationship between survival and RI (P = 0.0001) [21] .
In the IRMA-2 study, the potential impact of RI on patient survival has been assessed through a 2-year follow-up evaluation of 4267 cancer patients (solid tumors). The results showed that patients with a glomerular filtration rate (GFR) <60 ml/min/ 1.73 m² had a lower survival rate compared with patients with a GFR of ≥60 ml/min/1.73 m² in both univariate and multivariate analyses (P < 0.0001 and P = 0.0002, respectively) [22] .
These studies did not include ESRD patients, but suggested a possible correlation between cancer and renal disease [23] and its impact on mortality. Yet, the reasons for increased mortality in dialyzed patients with cancer have not been specifically addressed yet. Some authors have hypothesized that reduced survival could be related to cardiovascular complications of kidney disease as it is well known in renal impairment patients not presenting an oncology situation [24] . Moreover, such patients may have poorer physical status, although this could not be reliably addressed in our study. Another hypothesis could be that such observations are the consequences of inappropriate drug dosage adjustment [22] or therapeutic abstention (in ESRD patients). Indeed, inappropriate dosage in these patients can lead to overdosage and dose-related side-effects such as hematologic and gastric troubles for DNA cross-linking and anti-metabolite drugs, neurologic, and hematologic troubles for tubulin inhibitors (Table 4) .
Very little is known about cytotoxic drug management in ESRD patients and even less about the optimal timing and necessary dosage adjustments depending on dialysis sessions. A lack of knowledge and data concerning the use of systemic anticancer drugs in RI may lead to an improper use of chemotherapy and fatal toxic effects in these patients. Therefore, it is important to closely monitor all the extra renal dose-related toxic effects when using anticancer drugs in HD patients. However, ESRD patients must be given the chance to be treated like non-ESRD patients. In fact, some studies reported that the median survival of renal impairment patients with multiple myeloma was lower in patients without chemotherapy (i.e. 2 months) than in patients treated by vincristine, Adriamycin and dexamethasone therapy (e.g. 10 months), and melphalan protocols (e.g. 12 months) [25, 26] .
Other data on ESRD lung cancer patients showed that dialysis patients who underwent lung resection had a higher rate of postoperative complications than non-dialysis patients, but their mortality was not different [27] [28] [29] . Finally, these studies suggested that ESRD patients could be treated as non-dialysis cancer patients. However, it seems that physicians are reluctant to use anticancer drugs in dialysis cancer patients. It is true that dialysis patients require a specific attention, especially on their drug management. Despite the fact that the renal side-effects are no longer a problem in these patients, dialysis cancer patients are more exposed to the all non-renal dose-related side-effects, because most cytotoxic drugs used are excreted predominantly in the urine as unchanged drug or active/toxic metabolite(s).
In the CANDY study, most patients received at least one anticancer drug for which a specific attention was essential in terms of drug dosage adjustments (72%) and in terms of adequate timing of administration according to dialysis (82%). ESRD cancer patients may be treated as non-dialysis patients with the appropriate dosage. Therefore, it is crucial to use the available data to adjust the dose of anticancer drugs for these patients and to schedule the administration according to dialysis sessions. For example, dose adaptation is crucial in HD patients receiving platinum salts. For cisplatin, the initial doses of cisplatin in HD patients must be reduced by 50%. Cisplatin is a good example of drug management in HD patients; the dose must be reduced in order to avoid an overdose and tolerance issues, which may in turn question the possibility of repeating the course of the chemotherapy. Furthermore, cisplatin is highly and irreversibly bound to plasmatic proteins [30] . Free cisplatin is dialyzable and the loss of free cisplatin during HD is not compensated by bound cisplatin. Therefore, cisplatin must be given following HD sessions or on nondialysis days. For other drugs that are not substantially removed by dialysis, administration can be carried out anytime, before or after HD sessions (like doxorubicin and other drugs, Table 2 ).
We did not collect data on other medications, such as painkillers and anti-diabetic drugs, of which some drugs may need dosage adjustments in ESRD patients [31] . A multidisciplinary approach including the oncology, nephrology, and pharmacy departments is required to properly manage cancer patients, presenting ESRD and receiving all kinds of drugs potentially.
Anticancer drug management in dialysis patients is not easy because of the very few data available. Yet, some reviews, handbooks, or website (www.sitegpr.com) provide recommendations on cancer management in patients with renal impairment and especially in ESRD patients [16, 17, [31] [32] [33] [34] [35] [36] . These recommendations show that many anticancer drugs need dosage adjustment because of their pharmacokinetic modifications in ESRD patients. However, these recommendations derive from case reports and case series, and high-level evidence is still lacking in dialysis patients. Furthermore, there are still many drugs for which no data are available. For such drugs, it may be advisable to use any other appropriate drug for which clear dosage adjustment recommendations are available (whenever possible). This underlines the need for prospective pharmacokinetic studies to assess the characteristics of cytotoxic drugs in HD patients.
Additionally, such patient population should be studied in search of therapeutic algorithms, based on physical status, expected mortality from renal disease, and time on dialysis as well as type and stage of cancer.
conclusion
Cancer in ESRD patients is a rapidly growing concern for both oncologists and nephrologists as the risk of cancer is increased in ESRD patients [23] . Consequently, a growing proportion of ESRD patients need systemic anticancer treatments. The survival rate in these patients is lower compared with ESRD patients without cancer [8] . Noteworthy, ESRD is not an absolute contraindication to anticancer drugs in itself. Despite the fact that each patient and each clinical context is unique, it is essential to propose an adapted anticancer drug strategy (dosage, timing, monitoring) to dialysis patients (whenever possible) rather than contraindicating it systematically. However, most drugs require a specific renal management in dialysis patients, in terms of drug dosage and time of administration regarding the dialysis session as it was found in the CANDY study. Indeed, the clinical risks for the ESRD cancer patients are (i) developing extra-renal toxicity because of the increase in drug systemic expositions and (ii) having inefficient drug exposure because of early extensive elimination throughout dialysis. In order to prevent these two problems, it is crucial to use the available recommendations [34] and tools [31] to treat such patients adequately. Furthermore, pharmacokinetics studies are warranted in dialysis patients.
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